4D Molecular Therapeutics, Inc., was incorporated under the laws of the State of Delaware on March 11, 2015. The company is a late-stage biotechnology company focused on the development of durable, disease-targeting therapies, and its adeno-associated virus (AAV) vectors are developed using its proprietary Therapeutic Vector Evolution (TVE) platform. The TVE platform uses the principle of directed evolution to generate and screen AAV vectors in non-human primate models that have properties designed to overcome the limitations of traditional AAV and can target disease-related tissues with high unmet need through conventional and local administration routes. 4D's clinical research is mainly focused on vectors developed using the TVE platform for the treatment of retinal and pulmonary disease candidates.